Troriluzole

Generic Name: Troriluzole

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₆F_₃N_₅O_₄S

CAS Number: 1926203-09-9

Unique Ingredient Identifier: S7H48S6K7H

Background: Troriluzole is under investigation in clinical trial NCT03701399 (Troriluzole in Adult Subjects With Spinocerebellar Ataxia).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Trial in Adult Subjects With Spinocerebellar Ataxia

Phase 2

Completed

Conditions: Spinocerebellar Ataxia Genotype Type 6
Spinocerebellar Ataxia Genotype Type 8
Spinocerebellar Ataxia Genotype Type 1
Spinocerebellar Ataxia Genotype Type 2
Spinocerebellar Ataxias
Spinocerebellar Ataxia Genotype Type 3
Spinocerebellar Ataxia Genotype Type 7
Spinocerebellar Ataxia Genotype Type 10

Interventions: Drug: Placebo
Drug: Troriluzole

First Posted Date: 2016-11-10

Last Posted Date: 2024-10-16

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 141

Registration Number: NCT02960893

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy